Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs

JSR Life Sciences, LLC (JSR) and Blau Farmaceutica (Blau) (public company in Brazil B3 – BLAU3) today announced that Similis Bio (“Similis”), its recently launched business unit focused on biosimilar development, has signed its first development and license agreement with Blau Farmacêutica (“Blau”). The agreement ...

Related Keywords

United States ,Brazil ,America ,American ,Roberto Morais ,Blau Farmaceutica ,John Gabrielson ,Blau Farmac ,Similis Bio ,Life Sciences ,Senior Vice President ,Active Pharmaceutical Ingredients ,Executive Director ,Latin America ,Pharmaceutical Industry ,